1 x pre-designed iVORi siRNA for IN VIVO gene knockdown
Amount: 20, 100, 200 or 500 nmol
Quality control: IEX HPLC
In vivo grade: desalted, endotoxin-free
The iVORi siRNA technology has been invented by Riboxx to meet the pre-requisites of RNAi-drug development. The iVORi siRNA is the first siRNA developed exclusively for in vivo applications. The iVORi siRNA is highly stable in serum and body fluids, more potent and less toxic than commonly used siRNAs. These properties make it ideal for gene silencing experiments in vivo (animal models) and preclinical studies. Every iVORi siRNA is provided with the RNAi-cap technology.
The RNAi-cap technology offers several advantages:
- directional modulation of RISC unwinding of siRNA duplex, enhancing loading of the guide strand to the RISC complex. As a consequence, much less siRNA is needed for an effective gene silencing with a subsequent reduction of off-target effects 
- improved stability of siRNA duplex with subsequent improved half-life in body fluids.
 Nolte A, Ott K, Rohayem J, Walker T, Schlensak C, Wendel HP. Modification of small interfering RNAs to prevent off-target effects by the sense strand. N Biotechnol. 2013 Jan 25;30(2):159-65.
Download the flyer